1 1 Saracino Medical Limited 14268574 false 2024-01-01 2024-12-31 2024-12-31 The principal activity of the company is Specialists medical practice activities Digita Accounts Production Advanced 6.30.9574.0 true 14268574 2024-01-01 2024-12-31 14268574 2024-12-31 14268574 bus:OrdinaryShareClass1 2024-12-31 14268574 bus:OrdinaryShareClass2 2024-12-31 14268574 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 14268574 core:FurnitureFittings 2024-12-31 14268574 bus:SmallEntities 2024-01-01 2024-12-31 14268574 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 14268574 bus:FilletedAccounts 2024-01-01 2024-12-31 14268574 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 14268574 bus:RegisteredOffice 2024-01-01 2024-12-31 14268574 bus:Director1 2024-01-01 2024-12-31 14268574 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 14268574 bus:OrdinaryShareClass2 2024-01-01 2024-12-31 14268574 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 14268574 bus:Agent1 2024-01-01 2024-12-31 14268574 core:FurnitureFittings 2024-01-01 2024-12-31 14268574 countries:England 2024-01-01 2024-12-31 14268574 2023-12-31 14268574 core:FurnitureFittings 2023-12-31 14268574 2022-08-01 2023-12-31 14268574 2023-12-31 14268574 bus:OrdinaryShareClass1 2023-12-31 14268574 bus:OrdinaryShareClass2 2023-12-31 14268574 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 xbrli:pure iso4217:GBP xbrli:shares

Registration number: 14268574

Saracino Medical Limited
Unaudited Filleted Abridged Financial Statements
for the Year Ended 31 December 2024

Saracino Medical Limited

Contents

Company Information | 1
Abridged Balance Sheet | 2
Notes to the Unaudited Abridged Financial Statements | 3 to 4

Saracino Medical Limited

Company Information

Director | Mr Andrea Saracino

Registered office | Anglo House Worcester Road Stourport on Severn DY13 9AW

Accountants | Perrigo Consultants Limited Chartered Certified AccountantsAnglo House Worcester Road Stourport on Severn DY13 9AW

Saracino Medical Limited

(Registration number: 14268574)
Abridged Balance Sheet as at 31 December 2024

| Note | 2024 £ | 2023 £
Fixed assets |  |  |
Tangible assets | 4 | 3,787 | -
Current assets |  |  |
Cash at bank and in hand |  | 3,171 | 6,725
Creditors: Amounts falling due within one year |  | (231) | (2,068)
Net current assets |  | 2,940 | 4,657
Total assets less current liabilities |  | 6,727 | 4,657
Accruals and deferred income |  | (2,434) | (986)
Net assets |  | 4,293 | 3,671
Capital and reserves |  |  |
Called up share capital | 6 | 110 | 110
Retained earnings |  | 4,183 | 3,561
Shareholders' funds |  | 4,293 | 3,671

For the financial year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 15 September 2025

Mr Andrea Saracino Director

Saracino Medical Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 December 2024

1 | General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Anglo House
Worcester Road
Stourport on Severn
DY13 9AW

These financial statements were authorised for issue by the director on 15 September 2025.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Saracino Medical Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 December 2024

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

3 | Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2023 - 1).

4 | Tangible assets

| Fixtures and fittings £ | Total £
Cost or valuation
At 1 January 2024 | 5,049 | 5,049
At 31 December 2024 | 5,049 | 5,049
Depreciation
Charge for the year | 1,262 | 1,262
At 31 December 2024 | 1,262 | 1,262
Carrying amount
At 31 December 2024 | 3,787 | 3,787

5 | Debtors

Debtors includes £Nil (2023 - £Nil) due after more than one year.

6 | Share capital

Allotted, called up and fully paid shares

| 2024 | 2023
| No. | £ | No. | £
A of £1 each | 100 | 100 | 100 | 100
B of £1 each | 10 | 10 | 10 | 10
| 110 | 110 | 110 | 110